Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Chronic Spontaneous Urticaria · Asthma

Novartis India

Novartis Pharmaceuticals

Novartis India clinical programs — 46 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mumbai, IN
Founded
1996
Employees
2,240
Programs
341
Drugs
317
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Novartis India projects

46 ClinicalTrials.gov programs sponsored by Novartis India.

Novartis India has 46 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

46 programs

Clinical programs

  1. 68Ga-NNS309

    Novartis Pharmaceuticals

    Pancreatic Ductal Adenocarcinoma

    phase 1 small molecule active

    1 trial

  2. A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers

    Novartis Pharmaceuticals

    Advanced high-grade serous ovarian cancer (OC), Locally advanced unresectable or metastatic non-squamous non-small cell lung carcinoma (NSCLC)

    phase 1 other active

    1 trial

  3. CAAA601A52101

    Novartis Pharmaceuticals

    Glioblastoma

    phase 1 other active

    1 trial

  4. CAAA603C12101

    Novartis Pharmaceuticals

    Glioblastoma

    phase 1 other active

    1 trial

  5. CAAA617A12101

    Novartis Pharmaceuticals

    Metastatic Castration-Resistant Prostate Cancer

    phase 1 small molecule active

    1 trial

  6. CADPT01C12101

    Novartis Pharmaceuticals

    Advanced or metastatic BRAF V600 colorectal cancer.

    phase 1 other active

    1 trial

  7. CAIN457E22101

    Novartis Pharmaceuticals

    Polymyalgia rheumatica (PMR), Giant cell arteritis (GCA)

    phase 1 other active

    1 trial

  8. CDAK539A12102

    Novartis Pharmaceuticals

    Patients with advanced malignancies

    phase 1 other active

    1 trial

  9. CDAK539A12103

    Novartis Pharmaceuticals

    Advanced Malignancies and Hepatic Impairment

    phase 1 other active

    1 trial

  10. CDFF332A12101

    Novartis Pharmaceuticals

    Advanced, relapsed Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  11. CDKY709A12101C

    Novartis Pharmaceuticals

    Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma

    phase 1 other active

    1 trial

  12. CDLX313A12101

    Novartis Pharmaceuticals

    Parkinson’s Disease

    phase 1 other active

    1 trial

  13. CEGF816X2102

    Novartis Pharmaceuticals

    Patients with EGFR-mutant Non Small Cell Lung Cancer

    phase 1 other active

    1 trial

  14. CFKL480A02101

    Novartis Pharmaceuticals

    Advanced breast cancer and advanced NSCLC

    phase 1 other active

    1 trial

  15. CFXX489A12101

    Novartis Pharmaceuticals

    Locally advanced or metastatic unresectable colorectal cancer (CRC), Locally advanced unresectable or metastatic breast cancer (BC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)

    phase 1 other active

    1 trial

  16. CGCJ904A12101

    Novartis Pharmaceuticals

    Locally advanced unresectable or metastatic colorectal cancer (CRC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic soft tissue sarcoma (excluding GIST and Kaposi sarcoma), Locally advanced unresectable or metastatic HR+/HER2- ductal or lobular breast cancer (BC), Locally advanced unresectable or metastatic triple negative breast cancer (TNBC)

    phase 1 other active

    1 trial

  17. CHJB647A02101

    Novartis Pharmaceuticals

    Heart failure (HF)

    phase 1 other active

    1 trial

  18. CIAG933A12101

    Novartis Pharmaceuticals

    Advanced mesothelioma or other solid tumors harboring certain molecular alterations in the Hippo pathway

    phase 1 other active

    1 trial

  19. CIDH305X2101

    Novartis Pharmaceuticals

    Advanced malignancies that harbor IDH1R132 mutations

    phase 1 other active

    1 trial

  20. CINE963A02103

    Novartis Pharmaceuticals

    Malaria

    phase 1 other active

    1 trial

  21. CKFA115A12101

    Novartis Pharmaceuticals

    Thymic Carcinoma, Nasopharyngeal Cancer, Anal Cancer, Head and Neck Squamous Cell Carcinoma, Epithelial Ovarian Cancer, Cutaneous melanoma, Mesothelioma, Non-small cell lung cancer, Esophagogastric Cancer, Triple negative breast cancer, Microsatellite Instability High Colorectal Cancer, Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  22. CLDK378A2120C

    Novartis Pharmaceuticals

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  23. CLTP001A12101

    Novartis Pharmaceuticals

    Healthy volunteers

    phase 1 other active

    1 trial

  24. COJR520A12101

    Novartis Pharmaceuticals

    Chronic Kidney Disease

    phase 1 other active

    1 trial

  25. CPDR001X2X01B

    Novartis Pharmaceuticals

    Different types of advanced cancer

    phase 1 small molecule active

    1 trial

  26. CPIT565B12101

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  27. CPIT565C12101

    Novartis Pharmaceuticals

    Rheumatoid Arthritis

    phase 1 other active

    1 trial

  28. CTNO155X2101

    Novartis Pharmaceuticals

    Advanced solid tumors

    phase 1 other active

    1 trial

  29. CVAY736J12101

    Novartis Pharmaceuticals

    Relapsed/refractory Non Hodgkin Lymphoma

    phase 1 other active

    1 trial

  30. INC280 single agent

    Novartis Pharmaceuticals

    Non-Small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  31. Imatinib/Acetaminophen

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia (CML)

    phase 1 small molecule completed

    1 trial

  32. Indacaterol (QAB149)

    Novartis Pharmaceuticals

    Healthy

    phase 1 small molecule completed

    1 trial

  33. JSB462

    Novartis Pharmaceuticals

    Metastatic Prostate Cancer (mCRPC)

    phase 1 small molecule active

    1 trial

  34. KFA115

    Novartis Pharmaceuticals

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule active

    1 trial

  35. LDK378

    Novartis Pharmaceuticals

    Anaplastic Lymphoma Kinase (ALK)

    phase 1 small molecule completed

    1 trial

  36. LDT600 (Telbivudine)

    Novartis Pharmaceuticals

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  37. LEE011

    Novartis Pharmaceuticals

    Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

    phase 1 small molecule completed

    1 trial

  38. LGH447

    Novartis Pharmaceuticals

    Relapsed and Refractory Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  39. LGH447

    Novartis Pharmaceuticals

    AML and High Risk MDS

    phase 1 small molecule completed

    1 trial

  40. MBG453

    Novartis Pharmaceuticals

    Myelodysplastic Syndromes

    phase 1 small molecule terminated

    1 trial

  41. NIO752B12201

    Novartis Pharmaceuticals

    Alzheimer’s Disease

    phase 1 other active

    1 trial

  42. PDR001

    Novartis Pharmaceuticals

    Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

    phase 1 mab completed

    1 trial

  43. PDR001

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  44. Phase I study of MGY825 in patients with lung cancer

    Novartis Pharmaceuticals

    Advanced non-small cell lung cancer with or without NFE2L2/KEAP1/CUL3 mutations in adult patients

    phase 1 other active

    1 trial

  45. QEQ278

    Novartis Pharmaceuticals

    Carcinoma, Non-Small-Cell Lung

    phase 1 mab terminated

    1 trial

  46. Study of PIT565 in relapsed and/or refractory B-cell malignancies

    Novartis Pharmaceuticals

    Relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does Novartis India have?

46 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.